Depletion of Folate-Receptor-Positive Macrophages Leads to Alleviation of Symptoms and Prolonged Survival in Two Murine Models of Systemic Lupus Erythematosus
- 12 September 2007
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 4 (5), 679-685
- https://doi.org/10.1021/mp0700615
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease involving deposition of immune complexes in normal tissues and the consequent accumulation of immune cells and tissue injury. Activated macrophages are thought to contribute to disease pathogenesis by releasing inflammatory mediators that both cause direct tissue damage and attract other immune cells that augment inflammation. Previous studies in animal models of rheumatoid arthritis have shown that activated macrophages express a folate receptor that can be targeted with folate-linked haptens, leading to (1) marking of the activated macrophages with highly immunogenic haptens, (2) recognition of the marked cells by Fc receptor-expressing immune cells, and (3) destruction of the antibody-coated macrophages by the body's own immune system. Here we demonstrate that the same folate-hapten-targeted immunotherapy can greatly suppress symptoms of SLE in two animal models of the disease, resulting in reduced immune complex deposition, diminished damage to normal tissues, and prolonged animal survival.Keywords
This publication has 33 references indexed in Scilit:
- Peptide-Based Pharmacomodulation of a Cancer-Targeted Optical Imaging and Photodynamic Therapy AgentBioconjugate Chemistry, 2007
- Synthesis and Biological Evaluation of EC72: A New Folate-Targeted ChemotherapeuticBioconjugate Chemistry, 2005
- Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosusClinical Rheumatology, 2004
- Letter to the EditorLupus, 2003
- Attenuation of autoimmune disease in fas‐deficient mice by treatment with a cytotoxic benzodiazepineArthritis & Rheumatism, 2003
- Suppression of renal disease and mortality in the female NZBNZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acidLupus, 2001
- Expression in Transgenic Mice of Dominant Interfering Fas Mutations: A Model for Human Autoimmune Lymphoproliferative SyndromeClinical Immunology, 1999
- Expression of Th1/Th2cytokine mRNA in peritoneal exudative polymorphonuclear neutrophils and their effects on mononuclear cell Th1/Th2cytokine production in MRL‐lpr/lprmiceImmunology, 1998
- Enhanced Osteopontin Expression and Macrophage Infiltration in MRL-FaslprMice with Lupus NephritisAutoimmunity, 1998
- Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effectsEuropean Journal of Immunology, 1996